Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00763503 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00763503 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 26 participants.
The verdict
NCT00763503, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a multicenter, open-label study to assess systemic plasma levels of calcitriol, calcium homeostasis and safety in adults with plaque-type psoriasis under conditions of maximized use of CD 2027 3µg/g oily spray twice daily (6 g daily), applied to 20% of BSA for 3 weeks. There are a total of six visits: Pre-treatment period (Day -15, Day -8 and Day -1) and Treatment period (Day 1/ Baseline, Day 15 and Day 22).
Interventions
- DRUG CD 2027
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00763503
The ClinicalTrials.gov registry entry for NCT00763503 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD 2027 is the first listed.
NCT00763503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00763503 about?
NCT00763503 is a clinical study titled "Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis". This is a multicenter, open-label study to assess systemic plasma levels of calcitriol, calcium homeostasis and safety in adults with plaque-type psoriasis under conditions of maximized use of CD 2027 3µg/g oily spray twice daily (6 g daily), applied to 20% of BSA for 3 weeks. There are a total of ...
What is the current status of trial NCT00763503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2008-09. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00763503?
The interventions under investigation include: CD 2027 (DRUG).
Who is sponsoring clinical trial NCT00763503?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.